Abdelrahman R. Said

Mr. Abdelrahman R. Said

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2024 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
WEWalaa A. El-dakroury
Walaa A. El-dakroury
MZMoataz B. Zewail
Moataz B. Zewail
GAGihan Asaad
Gihan Asaad
HAHeba M.I. Abdallah
Heba M.I. Abdallah
MSMarwa E. Shabana
Marwa E. Shabana
ASAl-Aliaa M. Sallam
Al-Aliaa M. Sallam

23 November 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ASAbdelrahman R. Said
Abdelrahman R. Said
MAMona F. Arafa
Mona F. Arafa
WEWalaa A. El-dakroury
Walaa A. El-dakroury
SASultan Alshehri
Sultan Alshehri
GMGamal M. El Maghraby
Gamal M. El Maghraby
Cytarabine (CTR) is a hydrophilic anticancer drug used to treat leukemia. It suffers from poor permeability and intestinal metabolism, diminishing its oral bioavailability. Background/Objectives: The objective was to develop and evaluate niosomes and bilosomes for enhanced intestinal absorption; hence, oral bioavailability. Results: CTR-loaded niosomes and bilosomes with vesicle sizes of 152 and 204.3 nm were successfully prepared with acceptable properties. The presence of bile salts increased the zeta potential of bilosomes. The recorded entrapment efficiency of cytarabine was acceptable for such a hydrophilic drug. CTR-bilosomes showed a pH-dependent drug release pattern with preferred release in pH 6.8. Intestinal absorption behavior indicated a site-dependent CTR absorption pattern with unfavorable absorption in the distal intestine. Niosomal and bilosomal formulations enhanced intestinal absorption parameters with evidence for a predominant paracellular absorption mechanism that bypasses intestinal barriers. The investigation of the anti-leukemic effect of niosomal and bilosomal formulations indicated that both formulations ameliorated the blood parameters, reflecting significant improvement in leukemia treatment compared with the drug solution. Pathological examination of blood films revealed decreased blast cells in peripheral blood in groups treated with tested formulations. Methods: Tested formulations were prepared according to the pro-concentrate method and characterized for particle size, zeta potential, entrapment efficiency, and in vitro release. CTR-loaded niosomes and bilosomes were evaluated for enhanced intestinal absorption utilizing the single-pass in situ intestinal perfusion method in rabbits, and the anti-leukemic effect was assessed using the benzene-induced leukemia model in rats. Conclusions: This study introduced surfactant vesicles for enhanced oral bioavailability of CTR.

15 May 2024 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
ASAbdelrahman R. Said
Abdelrahman R. Said
GAGihan Asaad
Gihan Asaad
MSMarwa E. Shabana
Marwa E. Shabana
ASAlaa S. Sayed
Alaa S. Sayed
DEDalia H. Elfeky
Dalia H. Elfeky
WEWalaa A. El-dakroury
Walaa A. El-dakroury

15 July 2025 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
WEWalaa A. El-dakroury
Walaa A. El-dakroury
FEFatma Sa'eed EL-Tokhy
Fatma Sa'eed EL-Tokhy
GAGihan Asaad
Gihan Asaad
MSMarwa E. Shabana
Marwa E. Shabana
KEKareem H. Elsyed
Kareem H. Elsyed
ASAbdelrahman R. Said
Abdelrahman R. Said

1 May 2025 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
WEWalaa A. El-dakroury
Walaa A. El-dakroury
ASAbdelrahman R. Said
Abdelrahman R. Said
SMSherif S. Abdel Mageed
Sherif S. Abdel Mageed
ASAhmed Senbel
Ahmed Senbel
SSShahzada Khalid Sohail
Shahzada Khalid Sohail
OMOsama A. Mohammed
Osama A. Mohammed

8 January 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
WEWalaa A. El-dakroury
Walaa A. El-dakroury
SSSamar A. Salim
Samar A. Salim
ASAbdelrahman R. Said
Abdelrahman R. Said
GAGihan Asaad
Gihan Asaad
Mohamed Fayed abdelhameedMohamed Fayed abdelhameed
Mohamed Fayed abdelhameed
FEFatma Sa'eed EL-Tokhy
Fatma Sa'eed EL-Tokhy
Background/Objectives: Empagliflozin (EMPA) was repurposed for Alzheimer’s disease (AD) treatment via buccal delivery, exploiting novel nanofibers (NFs) integrating chitosan (Cs), silk fibroin (Fb), and poly(lactic acid) (PLA). Methods: EMPA-loaded Cs/Fb/PLA NFs were electrospun in different formulations to optimize the formulation parameters. The optimized formulation was then investigated for its enhanced in vivo effect. Results: Optimized nanofiber diameters ranged from 459 ± 173 to 668 ± 148 nm, possessing bead-free morphology confirmed by SEM and satisfactory mechanical properties. EMPA was successfully well-dispersed in the polymer matrix as evidenced by FTIR, XRD, and drug content. The optimized NFs displayed a hydrophilic surface (contact angle < 90°), and biphasic drug release with sustained EMPA liberation (84.98% over 24 h). In vivo, buccal EMPA-Cs/Fb/PLA NFs in an AlCl3-induced AD rat model significantly reduced brain-amyloid-β, phosphorylated tau, IL-1β, and AGER expression by 2.88-, 2.64-, 2.87-, and 2.50-fold, respectively, compared to positive controls, and improved locomotor activity (1.86-fold) and cognitive performance (T-maze) (4.17-fold). Compared to pure EMPA, the nanofiber formulation achieved further reductions in amyloid-β (1.78-fold), p-tau (1.42-fold), IL-1β (1.89-fold), and AGER (1.38-fold), with efficacy comparable to memantine. Histopathological examination revealed preservation of the hippocampal neuronal structure. Conclusions: The findings suggest EMPA-loaded Cs/Fb/PLA NFs as a promising non-invasive, sustained-release buccal delivery platform for AD therapy, offering multimodal neuroprotection through modulation of the Aβ–AGER–p-tau axis.